Immunome, Inc. (IMNM) Stock Price & Analysis
Immunome, Inc. (IMNM) closed at USD 17.4 on Thursday, October 15, 2026, up 1.16% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.2; the Oct 15, 2026 session ranged USD 17.08–17.61 on volume of 1,617,056 shares. Market capitalization is $2.05B, with a 52-week range of USD 14.64–30.06 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IMNM.md
Key facts (IMNM)
- Analysts: Buy (mean 1.88 on a 1–5 scale) (16 analysts), mean target USD 35.2 (range 24–40).
- Total return with dividends: 1Y +5.5% vs S&P 500 +18.1%; 5Y -1.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.59, revenue estimate $143K.
Analysts (IMNM)
Consensus Buy (mean 1.88 on a 1–5 scale), 16 analysts; mean target USD 35.2 (low 24, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Stifel | Initiated | Hold | $24 |
| 2026-09-21 | Alliance Global Partners | Initiated | Buy | $32 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $40 |
| 2026-08-12 | Truist Securities | Target raised | Buy | $37 → $38 |
| 2026-08-12 | Wedbush | Target raised | Outperform | $31 → $35 |
| 2026-07-21 | Wedbush | Reiterated | Outperform | $31 |
Total return (dividends reinvested) (IMNM)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +5.5% | -1.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +5.5% | -0.2% |
| Volatility (annualized) | 61.1% | 94.8% |
| Max drawdown | -42.3% (Aug 2026→Oct 2026) | -90.6% (Oct 2021→Dec 2022) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 17.4 |
|---|---|
| Change | ▲ 1.16% (up) |
| Previous Close | USD 17.2 |
| Open | USD 17.31 |
| Day Range | USD 17.08 – 17.61 |
| 52-Week Range | USD 14.64 – 30.06 |
| Volume | 1,617,056 shares |
| Market Cap | $2.05B |
| Exchange | NCM |
Technical Analysis (IMNM)
Nexqual's technical model rates IMNM "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 19.96 (oversold) |
| vs SMA50 | Below (USD 24.44) |
| MACD | -1.9 (negative) |
Analyst Ratings (IMNM)
Wall Street analysts rate IMNM "Buy" based on 16 analysts, with a mean price target of USD 35.2 (range USD 24–40), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 35.2 |
| High Target | USD 40 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 15 / 1 / 0 |
Earnings (IMNM)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.59 |
| Revenue Estimate | $142,860 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.65 vs est -0.5 ▼ miss |
| 2025-12-31 | USD -0.76 vs est -0.57 ▼ miss |
| 2025-09-30 | USD -0.65 vs est -0.54 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (IMNM)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -64.03% |
| Debt / Equity | 0.01 |
| Current Ratio | 15.08 |
| Total Cash | $520.00M |
| Total Debt | $4.74M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (IMNM)
Nexqual rates Immunome, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -23% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $520M cash vs $5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$209M (TTM) |
| Efficiency | Critical — ROE -64%, ROA -37.8% |
Ownership (IMNM)
| Insider Ownership | +6.32% |
|---|---|
| Institutional Ownership | +102.83% |
| Shares Outstanding | 118.00M |
| Float | 108.66M |
| Short % of Float | +17.25% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (IMNM)
Immunome, Inc. is led by Clay B. Siegall (age 64), Chairman, President & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman, President & CEO | Clay B. Siegall (age 64) |
|---|---|
| Chief Financial Officer | Max Rosett (age 35) |
| Chief Scientific Officer | Jack Higgins (age 45) |
| Executive Vice President of Commercial | Roee Shahar |
Major Backers & Investors (IMNM)
Notable institutional backers of Immunome, Inc. include T. Rowe Price, FMR, LLC, Fidelity, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 27.08% |
| FMR, LLC | 14.96% |
| Fidelity | 6.2% |
| Wellington Management | 4.59% |
| Redmile Group, LLC | 4.32% |
| Primecap Management Company | 4.03% |
| Driehaus Capital Management, LLC | 3.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.13% |
| Vanguard Group | 10.11% |
| State Street | 6.56% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt